World's Best Scientists 2026 revealed!
Erik Berntorp

Erik Berntorp

D-Index & Metrics

Medicine

D-Index
79
Citations
21754
World Ranking
17613
National Ranking
336

Overview

Erik Berntorp is affiliated with Lund University in Sweden, with a research focus in medicine, particularly hematology. Their scholarly work has concentrated on hemophilia treatment and related blood coagulation and thrombosis mechanisms.

Their research portfolio includes contributions to several prominent publication venues, notably:

  • Haemophilia
  • Research and Practice in Thrombosis and Haemostasis
  • Blood Reviews
  • Annals of Hematology
  • HemaSphere

Berntorp has been involved in multiple studies exploring various aspects of hemophilia, with main topics of work including:

  • Hemophilia Treatment and Research
  • Blood Coagulation and Thrombosis Mechanisms
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Platelet Disorders and Treatments
  • Orthopaedic implants and arthroplasty
  • Blood groups and transfusion
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Berntorp's frequent collaborators have included Jan Astermark, Pål André Holme, Riitta Lassila, Vuokko Nummi, and Alexander Solms, reflecting interdisciplinary research efforts within hematology and related fields.

Representative recent papers authored or co-authored by Berntorp include:

  • Optimising prophylaxis in haemophilia A: The ups and downs of treatment, 2021, Blood Reviews
  • Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A, 2020, Annals of Hematology
  • Alternative payment models for durable and potentially curative therapies: The case of gene therapy for haemophilia A, 2022, Haemophilia
  • The B-Natural study-The outcome of immune tolerance induction therapy in patients with severe haemophilia B, 2021, Haemophilia
  • Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A, 2022, Haemophilia

The body of work spans clinical pharmacokinetics, treatment strategies, and economic models for managing hemophilia therapies. This reflects an engagement with both scientific innovation and health economics considerations in rare blood disorders.

Best Publications

  • Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B

    I. M. Nilsson;E. Berntorp;T. Löfqvist;H. Pettersson

  • Increased fetal loss in women with heritable thrombophilia

    FE Preston;FR Rosendaal;ID Walker;E Briët

  • Impact, Diagnosis and Treatment of von Willebrand Disease*

    J E Sadler;P M Mannucci;Erik Berntorp;N Bochkov

  • A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

    Jan Astermark;Sharyne M. Donfield;Donna M. DiMichele;Alessandro Gringeri

  • Haemophilia prophylaxis in young patients–a long‐term follow‐up

    Thomas Löfqvist;Inga Marie Nilsson;Erik Berntorp;Holger Pettersson

  • Modern haemophilia care.

    Erik Berntorp;Amy D Shapiro

  • Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

    Jan Astermark;Johannes Oldenburg;Anna Pavlova;Erik Berntorp

  • Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized.

    Jan Astermark;Pia Petrini;Lilian Tengborn;Sam Schulman

  • Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIII

    Inga Marie Nilsson;Erik Berntorp;Olle Zettervall

  • Tranexamic acid - an old drug still going strong and making a revival.

    Lilian Tengborn;Margareta Blombäck;Erik Berntorp

  • Consensus perspectives on prophylactic therapy for haemophilia: summary statement.

    Erik Berntorp;Jan Astermark;S Björkman;V. S. Blanchette

  • Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

    Jan Astermark;Johannes Oldenburg;Joyce Carlson;Anna Pavlova

  • The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

    Jan Astermark;Erik Berntorp;G C White;B L Kroner

  • Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study

    Augusto B. Federici;Claudine Mazurier;Erik Berntorp;Christine A. Lee

  • Modern treatment of haemophilia.

    E Berntorp;V Boulyjenkov;D Brettler;M Chandy

  • Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.

    Cindy Leissinger;Alessandro Gringeri;Bülent Antmen;Erik Berntorp

  • Factor VIII inhibitors in mild and moderate-severity haemophilia A

    C. R M Hay;C. A. Ludlam;B. T. Colvin;F. G H Hill

  • Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients.

    S. Royal;W. Schramm;E. Berntorp;P. Giangrande

  • Arandomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

    Jan Astermark;Sharyne M. Donfield;Donna M. DiMichele;Alessandro Gringeri

  • INCREASED FETAL LOSS IN WOMEN WITH HERITABLE THROMBOPHILIA

    F. E. Preston;F. R. Rosendaal;I. D. Walker;E. Briet

Frequent Co-Authors

Sam Schulman
Sam Schulman McMaster University
Inga Marie Nilsson
Inga Marie Nilsson Lund University
Johannes Oldenburg
Johannes Oldenburg University of Bonn
Kathelijn Fischer
Kathelijn Fischer Utrecht University
Björn Dahlbäck
Björn Dahlbäck Lund University
Pier Mannuccio Mannucci
Pier Mannuccio Mannucci Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Flora Peyvandi
Flora Peyvandi University of Milan
Peter Collins
Peter Collins Cardiff University
Gilbert C. White
Gilbert C. White Medical College of Wisconsin
David Lillicrap
David Lillicrap Queen's University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens many doors, including a diverse range of online healthcare degrees that can complement or expand your medical training. For those interested in mental health, options like the shortest pmhnp program offer a fast-track path to becoming a Psychiatric Mental Health Nurse Practitioner, providing flexibility and accessibility for working professionals.

If your interests lean toward the business side of healthcare, consider an online health management degree. These programs develop leadership and administrative skills for roles in hospital or clinic management. Additionally, the cheapest mha programs make advanced education in healthcare administration accessible for students looking to minimize tuition costs.

For nurses aiming to reach the pinnacle of clinical expertise, msn to dnp programs online offer a practical route to earning a Doctor of Nursing Practice, often while continuing to work. These programs reflect the growing trend of online, flexible pathways that align with the evolving needs of medical professionals and healthcare systems.

Best Scientists Citing Erik Berntorp

Trending Scientists

Recently Published Articles